Pilot Study to Assess the Effects of AV608 on Irritable Bowel Syndrome

Irritable Bowel Syndrome (IBS) Clinical Trial

Official title:

A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Pilot Study to Assess the Effects of AV608 on Central Processing of Visceral Stimuli in Subjects With Irritable Bowel Syndrome

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00316550
• Other study ID #: AV608-107
• Status: Terminated
• Phase: Phase 1
• First received: April 19, 2006
• Last updated: February 15, 2008
• Start date: April 2006
• Est. completion date: September 2007

Study information

• Verified date: February 2008
• Source: Avera Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the effects of AV608, a neurokinin 1 (NK-1) antagonist, in subjects with Irritable Bowel Syndrome.

Description:

This is a single-center, randomized, double-blind, placebo-controlled, cross-over study to assess the effects of AV608 on brain processing of visceral stimuli and emotional visual cues in subjects with IBS. Female subjects between 18 and 65 years of age who meet diagnostic criteria for Irritable Bowel Syndrome will be eligible for the study.

Eligible subjects will complete a baseline fMRI imaging procedure that includes both emotional visual cues and visceral stimulation. All subjects who participate in the study will receive 3 weeks of treatment with AV608 and 3 weeks of treatment with placebo during the course of the study; the order of the two treatments for each subject will be randomly determined.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 24
• Est. completion date: September 2007
• Est. primary completion date: June 2007
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Female, 18 to 65 years of age, inclusive

• Current diagnosis of Irritable Bowel Syndrome (IBS)

• Subjects 50 years of age or older must have had a barium enema and flexible sigmoidoscopy or a colonoscopy and provide a record of this test

• Willing to participate in this study as evidenced by a signed, written informed consent form (ICF)

• If female and of child-bearing potential, willing to avoid pregnancy and practice adequate birth control from the time of study enrollment through at least 30 days after the final dose of study medication

• If female, negative pregnancy test results

• Right handed

• Ambulatory outpatient

• Agrees to refrain from blood donation during the course of the study

• Written and oral fluency in the English language

Exclusion Criteria:

• Evidence of structural abnormality of the gastrointestinal tract or GI diseases/conditions

• Current evidence or diagnosis of peptic ulcer

• Endoscopic bowel evaluation with evidence of cancer, inflammatory bowel disease, or other structural disease

• History of abdominal surgery such as adhesion lysis or any gastrointestinal surgery

• History of gastroesophageal reflux disease not controlled by a stable dose of medication

• Any evidence of or treatment of malignancy within the previous 5 years

• Clinical evidence of any disease that may interfere with participation in the study

• Existence of surgical or medical conditions which interfere with the absorption, distribution, metabolism and excretion of the study drug

• Symptoms of a significant clinical illness within the 2 weeks prior to Screening

• Type 1 diabetes mellitus, insulin-dependent Type 2 diabetes mellitus, and thyroid disorders or other endocrine disorders that are not well controlled by appropriate therapy

• A QTc interval of greater than or equal to 450 msec at Screening

• Presence of a psychotic disorder, bipolar disorder, alcohol or substance dependence (other than nicotine dependence) or eating disorder within the previous year according to DSM-IV-TR criteria

• Seizure disorder

• Subjects who have previously participated in a clinical trial for AV608 (previously known as NKP608 and CGP608)

• Positive drug test result at Screening

• Use of investigational drugs, products or devices within 30 days prior to Screening

• Planned use of certain drugs during the study that affect the central nervous system, gastrointestinal motility, autonomic activity or pain sensation

• Use of pimozide, terfenadine, astemizole, or cisapride during the study

• Presence of moderate or severe allergy

• Regular intake of more than 2 units of alcohol per day

• Pregnant or breast feeding

• Subjects with morbid obesity

• Subjects with metal implants or large tattoo

• Any clinically significant abnormalities on the Screening physical examination, ECG or laboratory tests

• Members of the investigative staff or their immediate family members

• Any other condition that the investigator believes would jeopardize the safety or rights of the subject or would render the subject unable to comply with the study protocol

• Regular use of more than 10 cigarettes per day

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Irritable Bowel Syndrome
• Irritable Bowel Syndrome (IBS)
• Syndrome

Intervention

Drug:
• AV608

Locations

Country	Name	City	State
United States	UCLA Center for Neurovisceral Sciences and Women's Health	Los Angeles	California

Sponsors (2)

Lead Sponsor	Collaborator
Avera Pharmaceuticals	University of California, Los Angeles

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary efficacy endpoint is the effect of AV608 on regional brain responses as measured by fMRI during conditioned and unconditioned visceral pain due to rectal distension.
Secondary	The effect of AV608 on regional brain responses to emotional visceral cues as measured by fMRI and the visceral pain threshold during rectal distension will be evaluated as secondary efficacy endpoints.